224 related articles for article (PubMed ID: 17986282)
21. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
22. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
23. 5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Délos S; Carsol JL; Fina F; Raynaud JP; Martin PM
Int J Cancer; 1998 Mar; 75(6):840-6. PubMed ID: 9506528
[TBL] [Abstract][Full Text] [Related]
24. Androgen metabolism in the human prostatic cancer cell line LNCaP.
Negri-Cesi P; Motta M
J Steroid Biochem Mol Biol; 1994 Oct; 51(1-2):89-96. PubMed ID: 7947355
[TBL] [Abstract][Full Text] [Related]
25. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.
Godoy A; Kawinski E; Li Y; Oka D; Alexiev B; Azzouni F; Titus MA; Mohler JL
Prostate; 2011 Jul; 71(10):1033-46. PubMed ID: 21557268
[TBL] [Abstract][Full Text] [Related]
26. Possible mechanisms of androgen resistance in 5 alpha-reductase deficiency: implications for the physiological roles of 5 alpha-reductases.
Hodgins MB
J Steroid Biochem; 1983 Jul; 19(1B):555-9. PubMed ID: 6887883
[TBL] [Abstract][Full Text] [Related]
27. Sex steroid hormone metabolism and prostate cancer.
Soronen P; Laiti M; Törn S; Härkönen P; Patrikainen L; Li Y; Pulkka A; Kurkela R; Herrala A; Kaija H; Isomaa V; Vihko P
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):281-6. PubMed ID: 15663991
[TBL] [Abstract][Full Text] [Related]
28. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer.
Uemura M; Honma S; Chung S; Takata R; Furihata M; Nishimura K; Nonomura N; Nasu Y; Miki T; Shuin T; Fujioka T; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2010 Aug; 101(8):1897-904. PubMed ID: 20560974
[TBL] [Abstract][Full Text] [Related]
29. The dihydrotestosterone (DHT) hypothesis of prostate cancer and its therapeutic implications.
Petrow V
Prostate; 1986; 9(4):343-61. PubMed ID: 3537993
[TBL] [Abstract][Full Text] [Related]
30. GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.
Reichardt JK
Front Biosci; 1999 Jul; 4():D596-600. PubMed ID: 10417059
[TBL] [Abstract][Full Text] [Related]
31. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.
Mohler JL; Titus MA; Wilson EM
Clin Cancer Res; 2011 Sep; 17(18):5844-9. PubMed ID: 21705451
[TBL] [Abstract][Full Text] [Related]
32. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
33. 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro.
Smith CM; Ballard SA; Worman N; Buettner R; Masters JR
J Clin Endocrinol Metab; 1996 Apr; 81(4):1361-6. PubMed ID: 8636334
[TBL] [Abstract][Full Text] [Related]
34. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
35. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3.
Provost PR; Blomquist CH; Godin C; Huang XF; Flamand N; Luu-The V; Nadeau D; Tremblay Y
Endocrinology; 2000 Aug; 141(8):2786-94. PubMed ID: 10919264
[TBL] [Abstract][Full Text] [Related]
36. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
37. Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.
Audet-Walsh É; Yee T; Tam IS; Giguère V
Endocrinology; 2017 Apr; 158(4):1015-1021. PubMed ID: 28324044
[TBL] [Abstract][Full Text] [Related]
38. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
Hirsch KS; Jones CD; Audia JE; Andersson S; McQuaid L; Stamm NB; Neubauer BL; Pennington P; Toomey RE; Russell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5277-81. PubMed ID: 8389478
[TBL] [Abstract][Full Text] [Related]
39. Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders.
Ito K; Suzuki T; Akahira J; Moriya T; Kaneko C; Utsunomiya H; Yaegashi N; Okamura K; Sasano H
Int J Cancer; 2002 Jun; 99(5):652-7. PubMed ID: 12115497
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 5α-reductase activity and isoenzymes in human abdominal adipose tissues.
Fouad Mansour M; Pelletier M; Tchernof A
J Steroid Biochem Mol Biol; 2016 Jul; 161():45-53. PubMed ID: 26855069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
